News and Announcements
Hazer Group Ltd (ASX:HZR) Completes Commission of Pre-Pilot Plant
- Published July 06, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Hazer Group Ltd (ASX:HZR) is pleased to announce the success of commissioning of the Company’s pre-pilot plant, located in St Marys in Western Sydney. This marks a significant inflexion point in Hazer’s development trajectory, with the pre-pilot plant now ready to commence the operational experimentation phase.
KEY TAKEAWAYS:
- Commissioning of Pre-Pilot Plant now complete.
- Marks and important milestone in Hazers scale-up road map.
- Pre-Pilot Plant now ready to commence operational experimentation phase.
Furthermore, various process design and operational optimisation opportunities have already been identified during the commissioning phase, and will be progressed as part of ongoing operations of the pre-pilot plant.
Hazer Group Managing Director Geoff Pocock said: “This successful commissioning will now allow Hazer to continue its transition from laboratory-based development to functional industrial technology. The pre-pilot plant enables us to evaluate the performance of the Hazer Process at temperature, pressure and in a fluidised state and advance our development strategy to demonstrate our technology can operate at this scale and beyond.”
Once operational in fully continuous mode, the pre-pilot plant will be used to generate data necessary for the design and construction of Hazer’s next plant – a commercial prototype facility that is expected to be of a greater scale, ideally suited to the vehicle refuelling market.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
